An investigation on behalf of investors in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares over potential wrongdoing at Alnylam Pharmaceuticals was announced and NASDAQ:ALNY stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 07/28/2015 -- The Shareholders Foundation announces that an investigation for investors in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares was initiated over potential breaches of fiduciary duties by certain Alnylam Pharmaceuticals officers and directors.
Investors who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Alnylam Pharmaceuticals officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
Alnylam Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $47.17 million in 2013 to $50.56 million in 2014 while its respective Net Loss increased from $89.22 million to $360.39 million. Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) grew from $53.71 per share in August 2014 to as high as $138.73 per share in June 2015.
Those who purchased shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com